TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

Core Insights - TG Therapeutics has secured a new five-year, $750 million senior secured credit facility with Blue Owl Capital, allowing for a net raise of $500 million in non-dilutive capital after repaying an existing $250 million facility [1][3] - The company has increased its share repurchase program from $100 million to $300 million, having repurchased approximately $38 million of common stock at an average price of $28.98 per share as of March 18, 2026 [2] Financial Position - The new credit facility enhances the financial position of TG Therapeutics with improved terms compared to the previous facility, providing substantial non-dilutive capital to support share repurchases and business development [3] - The total facility size can reach up to $1 billion, contingent upon mutual agreement between TG and Blue Owl [1] Strategic Initiatives - The expansion of the share repurchase program reflects the company's confidence in its business and commitment to long-term shareholder value [3] - TG Therapeutics continues to demonstrate strong commercial execution with its product BRIUMVI and maintains a disciplined approach to growth [3] Product Information - BRIUMVI is a novel monoclonal antibody targeting CD20-expressing B-cells, indicated for the treatment of adults with relapsing multiple sclerosis (RMS) [4][5] - The drug is designed to efficiently deplete B-cells at low doses through a process called glycoengineering [4] Company Overview - TG Therapeutics is a biotechnology company focused on developing and commercializing treatments for B-cell diseases, with BRIUMVI approved for RMS in the U.S. and several other countries [27] - The company aims to advance its pipeline while supporting the growth of BRIUMVI through strategic financial maneuvers [3][27]